The Multifaceted Role of Low Dose IV Ketamine to Control Debilitating Neuropathic Pain Conditions
Abstract
Ketamine has been around since the 1960s, providing analgesia, amnesia, hypnosis and has been used to treat acute pain, chronic pain, acute on chronic pain, neuropathic pain, refractory head pain, depression, and post-traumatic stress disorder (PTSD).
Depression, posttraumatic-stress disorder, and chronic regional pain syndrome (CRPS), can all be extremely debilitating pathologies from a functional, emotional, and spiritual perspective. The mind, body, and spirit are all interconnected, and play a crucial role in the management of these medical conditions. Though oral medications have been used as a mainstay therapy, there can be some limitations with achieving therapeutic effects.
Ketamine is a mixture of R-ketamine and S-ketamine, each demonstrating unique qualities in aiding treatment. Additional metabolism of R-ketamine and S-ketamine has resulted in distinctive metabolites providing treatment for depression, suicidal ideations, and complex regional pain syndrome. Intravenous ketamine administration has provided therapeutic effects for headaches refractory to standard therapy.
The utilization of ketamine continues to evolve and continues to provide beneficial clinical treatments, with limited side effects.
Ketamine has been around since the 1960s, providing analgesia, amnesia, hypnosis and has been used to treat acute pain, chronic pain, acute on chronic pain, neuropathic pain, refractory head pain, depression, and post-traumatic stress disorder (PTSD).
Depression, posttraumatic-stress disorder, and chronic regional pain syndrome (CRPS), can all be extremely debilitating pathologies from a functional, emotional, and spiritual perspective. The mind, body, and spirit are all interconnected, and play a crucial role in the management of these medical conditions. Though oral medications have been used as a mainstay therapy, there can be some limitations with achieving therapeutic effects.
Ketamine is a mixture of R-ketamine and S-ketamine, each demonstrating unique qualities in aiding treatment. Additional metabolism of R-ketamine and S-ketamine has resulted in distinctive metabolites providing treatment for depression, suicidal ideations, and complex regional pain syndrome. Intravenous ketamine administration has provided therapeutic effects for headaches refractory to standard therapy.
The utilization of ketamine continues to evolve and continues to provide beneficial clinical treatments, with limited side effects.
Keywords
Full Text:
PDFReferences
Gao M, Rejaei D, Liu H. Ketamine use in current clinical practice. Acta Pharmacologica Sinica. 2016;37(7):865-872. doi:10.1038/aps.2016.5.
Radvansky BM, Puri S, Sifonios AN, Eloy JD, Le V. Ketamine—A Narrative Review of Its Uses in Medicine. American Journal of Therapeutics. 2016;23(6). doi:10.1097/mjt.0000000000000257.
Pomeroy JL, Marmura MJ, Nahas SJ, Viscusi ER. Ketamine Infusions for Treatment Refractory Headache. Headache: The Journal of Head and Face Pain. 2016;57(2):276-282. doi:10.1111/head.13013.
Schwenk ES, Dayan AC, Rangavajjula A, et al. Ketamine for Refractory Headache. Regional Anesthesia and Pain Medicine. 2018:1. doi:10.1097/aap.0000000000000827.
Ketamine Mechanism of Action. Anesthesia General. November 2017. anesthesiageneral.com/ketamine-mechanism-of-action.
Yang C, Yang J, Luo A, Hashimoto K. Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites. Translational Psychiatry. 2019;9(1). doi:10.1038/s41398-019-0624-1.
Mathisen LC, Skjelbred P, Skoglund LA, Øye I. Effect of ketamine, an NMDA receptor inhibitor, in acute and chronic orofacial pain. Pain. 1995;61(2):215-220. doi:10.1016/0304-3959(94)00170-j.
Oye I, Paulsen O, Maurset A. Effects of ketamine on sensory perception: evidence for a role of N-methyl-D-aspartate receptors. Journal of Pharmacology and Experimental Therapeutics . 1992;260(3).
Vollenweider F, Leenders K, Øye I, Hell D, Angst J. Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET). European Neuropsychopharmacology. 1997;7(1):25-38. doi:10.1016/s0924-977x(96)00042-9.
Zhang J-C, Li S-X, Hashimoto K. R (−)-ketamine shows greater potency and longer lasting antidepressant effects than S ( )-ketamine. Pharmacology Biochemistry and Behavior. 2014;116:137-141. doi:10.1016/j.pbb.2013.11.033.
Andrade, Chittaranjan. “Ketamine for Depression, 3: Does Chirality Matter?” The Journal of Clinical Psychiatry, vol. 78, no. 06, 28 June 2017, doi:10.4088/jcp.17f11681.
Hashimoto K. Rapid‐acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective. Psychiatry and Clinical Neurosciences. 2019;73(10):613-627. doi:10.1111/pcn.12902.
Zanos P. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. European Neuropsychopharmacology. 2017;27. doi:10.1016/s0924-977x(17)30999-9.
Reinstatler L, Youssef NA. Ketamine as a Potential Treatment for Suicidal Ideation: A Systematic Review of the Literature. Drugs in R&D. 2015;15(1):37-43. doi:10.1007/s40268-015-0081-0.
Price RB, Iosifescu DV, Murrough JW, et al. Effects Of Ketamine On Explicit And Implicit Suicidal Cognition: A Randomized Controlled Trial In Treatment-Resistant Depression. Depression and Anxiety. 2014;31(4):335-343. doi:10.1002/da.22253.
Jahangiri L, Kesmati M, Najafzadeh H. Evaluation of analgesic and anti-inflammatory effect of nanoparticles of magnesium oxide in mice with and without ketamine. European Review for Medical and Pharmacological Sciences . 2013;17(20).
Dale O, Somogyi AA, Li Y, Sullivan T, Shavit Y. Does Intraoperative Ketamine Attenuate Inflammatory Reactivity Following Surgery? A Systematic Review and Meta-Analysis. Anesthesia & Analgesia. 2012;115(4):934-943. doi:10.1213/ane.0b013e3182662e30.
Gao M, Jin W, Qian Y, Ji L, Feng G, Sun J. Effect of N-methyl-D-aspartate receptor antagonist on T helper cell differentiation induced by phorbol-myristate-acetate and ionomycin. Cytokine. 2011;56(2):458-465. doi:10.1016/j.cyto.2011.06.022.
Remérand F, Tendre CL, Baud A, et al. The Early and Delayed Analgesic Effects of Ketamine After Total Hip Arthroplasty: A Prospective, Randomized, Controlled, Double-Blind Study. Anesthesia & Analgesia. 2009;109(6):1963-1971. doi:10.1213/ane.0b013e3181bdc8a0.
Welters I, Feurer M-K, Preiss V, et al. Continuous S -( )-ketamine administration during elective coronary artery bypass graft surgery attenuates pro-inflammatory cytokine response during and after cardiopulmonary bypass. British Journal of Anaesthesia. 2011;106(2):172-179. doi:10.1093/bja/aeq341.
Uher R, Payne JL, Pavlova B, Perlis RH. Major Depressive Disorder In Dsm-5: Implications For Clinical Practice And Research Of Changes From Dsm-Iv. Depression and Anxiety. 2013;31(6):459-471. doi:10.1002/da.22217.
Coccaro EF. New Hope for Patients with Major Depressive Disorder? New England Journal of Medicine. 2019;381(10):980-981. doi:10.1056/nejme1907638.
Koskie, Brandi. “Depression: Facts, Statistics, and You.” Healthline, Healthline Media, 14 May 2019, www.healthline.com/health/depression/facts-statistics-infographic#1.
Kim J-W, Monteggia LM. Increasing doses of ketamine curtail antidepressant responses and suppress associated synaptic signaling pathways. Behavioural Brain Research. 2020;380:112378. doi:10.1016/j.bbr.2019.112378.
Deyama S, Duman RS. Neurotrophic mechanisms underlying the rapid and sustained antidepressant actions of ketamine. Pharmacology Biochemistry and Behavior. 2020;188:172837. doi:10.1016/j.pbb.2019.172837.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-5. Washington, DC: American Psychiatric Association; 2013.
Liriano F, Hatten C, Schwartz TL. Ketamine as treatment for post-traumatic stress disorder: a review. Drugs in Context. 2019;8:1-7. doi:10.7573/dic.212305.
Rasmussen KG. Ketamine for Posttraumatic Stress Disorder. JAMA Psychiatry. 2015;72(1):94. doi:10.1001/jamapsychiatry.2014.1621.
Krystal JH, Abdallah CG, Averill LA, et al. Synaptic Loss and the Pathophysiology of PTSD: Implications for Ketamine as a Prototype Novel Therapeutic. Current Psychiatry Reports. 2017;19(10). doi:10.1007/s11920-017-0829-z.
Mcghee LL, Maani CV, Garza TH, Gaylord KM, Black IH. The Correlation Between Ketamine and Posttraumatic Stress Disorder in Burned Service Members. The Journal of Trauma: Injury, Infection, and Critical Care. 2008;64(Supplement). doi:10.1097/ta.0b013e318160ba1d.
Zimmerman JM, Maren S. NMDA receptor antagonism in the basolateral but not central amygdala blocks the extinction of Pavlovian fear conditioning in rats. European Journal of Neuroscience. 2010. doi:10.1111/j.1460-9568.2010.07223.x.
Goebel A, Bisla J, Carganillo R, et al. A randomised placebo-controlled Phase III multicentre trial: low-dose intravenous immunoglobulin treatment for long-standing complex regional pain syndrome (LIPS trial). Efficacy and Mechanism Evaluation. 2017;4(5):1-82. doi:10.3310/eme04050.
Zarate CA, Brutsche N, Laje G, et al. Relationship of Ketamines Plasma Metabolites with Response, Diagnosis, and Side Effects in Major Depression. Biological Psychiatry. 2012;72(4):331-338. doi:10.1016/j.biopsych.2012.03.004.
Zanos P, Moaddel R, Morris PJ, et al. Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms. Pharmacological Reviews. 2018;70(3):621-660. doi:10.1124/pr.117.015198.
Das V, Kroin JS, Moric M, Buvanendran A. Biochemical and Pharmacological Characterization of a Mice Model of Complex Regional Pain Syndrome. Regional Anesthesia and Pain Medicine. 2017;42(4):507-516. doi:10.1097/aap.0000000000000622.
Tajerian M, Clark JD. New Concepts in Complex Regional Pain Syndrome. Hand Clinics. 2016;32(1):41-49. doi:10.1016/j.hcl.2015.08.003.
Xu Q, Yaksh TL. A brief comparison of the pathophysiology of inflammatory versus neuropathic pain. Current Opinion in Anaesthesiology. 2011;24(4):400-407. doi:10.1097/aco.0b013e32834871df.
Borsook D, Dodick DW. Taking the headache out of migraine. Neurology: Clinical Practice. 2015;5(4):317-325. doi:10.1212/cpj.0000000000000171.
Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1-211. doi:10.1177/0333102417738202.
GBD 2010 The Global Burden of Disease Study 2010. Lancet 2012;380:2053–260.
GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016; 388: 1545–1602.
Clinch C (2011) Chapter 28. Evaluation & Management of headache - CURRENT Diagnosis & Treatment in family medicine. In: South-Paul JE, Matheny SC, Lewis EL (eds) Lange Current Series, Third edn. McGraw-Hill. isbn:9780071624367
Silberstein SD, Lipton RB, Dodick DW. Operational Diagnostic Criteria for Chronic Migraine: Expert Opinion. Headache: The Journal of Head and Face Pain. 2014;54(7):1258-1266. doi:10.1111/head.12407.
Silberstein SD, Dodick DW, Pearlman S. Defining the Pharmacologically Intractable Headache for Clinical Trials and Clinical Practice. Headache: The Journal of Head and Face Pain. 2010;50(9):1499-1506. doi:10.1111/j.1526-4610.2010.01764.x.
Nicolodi M, Sicuteri F. Exploration of NMDA receptors in migraine: therapeutic and theoretic implications. Int J Clin Pharmacol Res. 1995;15(5-6):181-9. PubMed PMID: 8835616.
Kaube H, Herzog J, Kaufer T, Dichgans M, Diener HC. Aura in some patients with familial hemiplegic migraine can be stopped by intranasal ketamine. Neurology. 2000;55(1):139-141. doi:10.1212/wnl.55.1.139.
Granata L, Niebergall H, Langner R, Agosti R, Sakellaris L. Ketamin i. v. zur Behandlung von Clusterkopfschmerz. Der Schmerz. 2016;30(3):286-288. doi:10.1007/s00482-016-0111-z.
Pomeroy JL, Marmura MJ, Nahas SJ, Viscusi ER. Ketamine Infusions for Treatment Refractory Headache. Headache: The Journal of Head and Face Pain. 2016;57(2):276-282. doi:10.1111/head.13013.
Schwenk ES, Dayan AC, Rangavajjula A, et al. Ketamine for Refractory Headache. Regional Anesthesia and Pain Medicine. 2018:1. doi:10.1097/aap.0000000000000827.
Practice Guidelines for Sedation and Analgesia by Non-Anesthesiologists. Anesthesiology. 2002;96(4):1004-1017. doi:10.1097/00000542-200204000-00031.
Harden RN, Oaklander AL, Burton AW, et al. Complex Regional Pain Syndrome: Practical Diagnostic and Treatment Guidelines, 4th Edition. Pain Medicine. 2013;14(2):180-229. doi:10.1111/pme.12033.
Zanos P, Gould TD. Mechanisms of ketamine action as an antidepressant. Molecular Psychiatry. 2018;23(4):801-811. doi:10.1038/mp.2017.255.
Pradhan B, Parikh T, Makani R, Sahoo M. Ketamine, Transcranial Magnetic Stimulation, and Depression Specific Yoga and Mindfulness Based Cognitive Therapy in Management of Treatment Resistant Depression: Review and Some Data on Efficacy. Depression Research and Treatment. 2015;2015:1-14. doi:10.1155/2015/842817.
Pradhan B, Sharma A. Editorial (Thematic Issue: The Time has Come for Integrating Complementary Medicine into Psychiatry). Adolescent Psychiatry. 2015;5(2):71-72. doi:10.2174/221067660502150430154342.
Felder JN, Dimidjian S, Segal Z. Collaboration in Mindfulness-Based Cognitive Therapy. Journal of Clinical Psychology. 2012;68(2):179-186. doi:10.1002/jclp.21832.
Piet J, Hougaard E. The effect of mindfulness-based cognitive therapy for prevention of relapse in recurrent major depressive disorder: A systematic review and meta-analysis. Clinical Psychology Review. 2011;31(6):1032-1040. doi:10.1016/j.cpr.2011.05.002.
DOI: http://dx.doi.org/10.18103/imr.v6i3.853
Refbacks
- There are currently no refbacks.